Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors
Business Wire•02/11/2026•08:00 ET
0
Key Highlights
- ➤Xeris (XERS) appoints Menassie M. Taddese to its Board of Directors
- ➤Taddese joins Xeris’ Audit Committee effective immediately
- ➤Taddese brings nearly 30 years of global biopharmaceutical leadership experience
- ➤Xeris identifies XP-8121 as a Phase 3-ready hypothyroidism treatment candidate
Expert Statements
John Shannon, Chairman and Chief Executive Officer of Xeris
“We are delighted to welcome Menassie to the Xeris Board. His experience leading complex, pharmaceutical businesses, driving financial performance, and overseeing public company audit and governance matters will bring a valuable perspective to our Board. We look forward to benefiting from his leadership as we continue to execute our strategy and pursue long-term value creation.”
Menassie M. Taddese, Xeris Board Director
“I am pleased to join the Xeris Board of Directors as they continue to grow their commercial portfolio and advance their late-stage clinical pipeline medicine XP-8121. I look forward to working with my fellow Board members and the Xeris management team as they continue their disciplined execution.”
Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors
Experienced biopharmaceutical executive brings global commercial leadership, financial expertise, and public company governance experience
Get started
Create a free account to read the full story.